Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1941)
•••
Post by Oden6570on Sep 03, 2024 7:54am
613 Views
Post# 36205784

AI Bart suggests these dance partners :-)

AI Bart suggests these dance partners :-) Notice the heading of news release !!!!!

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery

Theralase Inc. has announced that its lead drug formulation, Ruvidar™, has been proven more effective than Acyclovir in the destruction of the Herpes Simplex Virus1. This is a significant development, and partnering with a major pharmaceutical company could help in the commercialization of this discovery.

Here are some of the big pharmaceutical companies that could be well-suited for such a partnership:

  1. Johnson & Johnson - Known for its extensive experience in pharmaceuticals and consumer health products2.
  2. Pfizer - A global leader in pharmaceuticals with a strong focus on antiviral drugs2.
  3. Gilead Sciences - Specializes in antiviral drugs, including treatments for HIV and hepatitis3.
  4. Merck & Co. - Has a strong portfolio in infectious diseases and vaccines2.
  5. GlaxoSmithKline (GSK) - Known for its work in vaccines and antiviral medications3.

These companies have the resources, expertise, and global reach to help Theralase Inc. bring Ruvidar™ to market effectively.




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities